Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Iovance Biotherapeutics (IOVA) over the last 11 years, with Q3 2025 value amounting to $2.9 million.

  • Iovance Biotherapeutics' Depreciation & Amortization (CF) fell 206.67% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.2 million, marking a year-over-year increase of 982.39%. This contributed to the annual value of $12.0 million for FY2024, which is 344.83% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Depreciation & Amortization (CF) stood at $2.9 million for Q3 2025, which was down 206.67% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Depreciation & Amortization (CF) ranged from a high of $4.0 million in Q4 2024 and a low of $2.8 million during Q1 2023
  • For the 3-year period, Iovance Biotherapeutics' Depreciation & Amortization (CF) averaged around $3.1 million, with its median value being $3.0 million (2023).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 3485.41% in 2024, then tumbled by 666.67% in 2025.
  • Iovance Biotherapeutics' Depreciation & Amortization (CF) (Quarter) stood at $3.0 million in 2023, then skyrocketed by 34.85% to $4.0 million in 2024, then fell by 26.92% to $2.9 million in 2025.
  • Its Depreciation & Amortization (CF) was $2.9 million in Q3 2025, compared to $3.4 million in Q2 2025 and $2.8 million in Q1 2025.